Role of TDM‐based dose adjustments for taxane anticancer drugs

This review article discusses the ongoing debate on the most effective and safe taxane regimen, and suggests therapeutic drug monitoring be recommended for NSCLC patients receiving 3-weekly paclitaxel in combination with a platinum drug, who are at particular risk for neuropathy

British Journal of Clinical Pharmacology